A. Kingsnorth, E. Moltchanova, Jonah J C Thomas, Maxine E. Whelan, M. Orme, D. Esliger, M. Hobbs
{"title":"Interchangeability of Research and Commercial Wearable Device Data for Assessing Associations With Cardiometabolic Risk Markers","authors":"A. Kingsnorth, E. Moltchanova, Jonah J C Thomas, Maxine E. Whelan, M. Orme, D. Esliger, M. Hobbs","doi":"10.1123/jmpb.2022-0050","DOIUrl":null,"url":null,"abstract":"Introduction: While there is evidence on agreement, it is unknown whether commercial wearables can be used as surrogates for research-grade devices when investigating links with markers of cardiometabolic risk. Therefore, the aim of this study was to investigate whether data from a commercial wearable device could be used to assess associations between behavior and cardiometabolic risk markers, compared with physical activity from a research-grade monitor. Methods: Forty-five adults concurrently wore a wrist-worn Fitbit Charge 2 and a waist-worn ActiGraph wGT3X-BT during waking hours over 7 consecutive days. Log-linear regression models were fitted, and predictive fit via a one-out cross-validation was performed for each device between behavioral (steps, and light and moderate-to-vigorous physical activity) and cardiometabolic variables (body mass index, weight, body fat percentage, systolic and diastolic blood pressure, glycated haemoglobin, grip strength, estimated maximal oxygen uptake, and waist circumference). Results: Overall, step count was the most consistent predictor of cardiometabolic risk factors, with negative associations across both Fitbit and ActiGraph devices for body mass index (−0.017 vs. −0.020, p < .01), weight (−0.014 vs. −0.017, p < .05), body fat percentage (−0.021 vs. −0.022, p < .01), and waist circumference (−0.013 vs. −0.015, p < .01). Neither device was found to provide a consistently better prediction across all included cardiometabolic risk markers. Conclusions: Step count data from a commercial-grade wearable device showed similar associations and predictive relationships with cardiometabolic risk markers compared with a research-grade wearable device, providing preliminary support for their use in health research.","PeriodicalId":73572,"journal":{"name":"Journal for the measurement of physical behaviour","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal for the measurement of physical behaviour","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1123/jmpb.2022-0050","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: While there is evidence on agreement, it is unknown whether commercial wearables can be used as surrogates for research-grade devices when investigating links with markers of cardiometabolic risk. Therefore, the aim of this study was to investigate whether data from a commercial wearable device could be used to assess associations between behavior and cardiometabolic risk markers, compared with physical activity from a research-grade monitor. Methods: Forty-five adults concurrently wore a wrist-worn Fitbit Charge 2 and a waist-worn ActiGraph wGT3X-BT during waking hours over 7 consecutive days. Log-linear regression models were fitted, and predictive fit via a one-out cross-validation was performed for each device between behavioral (steps, and light and moderate-to-vigorous physical activity) and cardiometabolic variables (body mass index, weight, body fat percentage, systolic and diastolic blood pressure, glycated haemoglobin, grip strength, estimated maximal oxygen uptake, and waist circumference). Results: Overall, step count was the most consistent predictor of cardiometabolic risk factors, with negative associations across both Fitbit and ActiGraph devices for body mass index (−0.017 vs. −0.020, p < .01), weight (−0.014 vs. −0.017, p < .05), body fat percentage (−0.021 vs. −0.022, p < .01), and waist circumference (−0.013 vs. −0.015, p < .01). Neither device was found to provide a consistently better prediction across all included cardiometabolic risk markers. Conclusions: Step count data from a commercial-grade wearable device showed similar associations and predictive relationships with cardiometabolic risk markers compared with a research-grade wearable device, providing preliminary support for their use in health research.